Consolidated Statement Of Income

KYORIN Pharmaceutical Co., Ltd. - Filing #7573971

Concept 2022-04-01 to
2022-12-31
2021-04-01 to
2021-12-31
Consolidated statement of income
Statement of income
Net sales
80,707,000,000 JPY
77,717,000,000 JPY
Ordinary income
Other operating income
Share of profit of entities accounted for using equity method
JPY
24,000,000 JPY
Operating expenses
Selling, general and administrative expenses
32,352,000,000 JPY
33,313,000,000 JPY
Operating expenses
Ordinary expenses
Other operating expenses
Share of loss of entities accounted for using equity method
5,000,000 JPY
JPY
Cost of sales
43,652,000,000 JPY
41,477,000,000 JPY
Net sales
Gross profit (loss)
37,055,000,000 JPY
36,240,000,000 JPY
Operating profit (loss)
4,702,000,000 JPY
2,926,000,000 JPY
Ordinary profit (loss)
5,336,000,000 JPY
3,515,000,000 JPY
Operating expenses
Research and development expenses
7,156,000,000 JPY
6,571,000,000 JPY
Non-operating income
Interest income
6,000,000 JPY
2,000,000 JPY
Dividend income
449,000,000 JPY
409,000,000 JPY
Other
143,000,000 JPY
133,000,000 JPY
Non-operating income
712,000,000 JPY
654,000,000 JPY
Cost of sales
Selling, general and administrative expenses
Extraordinary income
1,332,000,000 JPY
0 JPY
Non-operating expenses
Interest expenses
50,000,000 JPY
51,000,000 JPY
Other
20,000,000 JPY
10,000,000 JPY
Non-operating expenses
78,000,000 JPY
65,000,000 JPY
Extraordinary losses
707,000,000 JPY
17,000,000 JPY
Impairment losses
105,000,000 JPY
JPY
Profit (loss) before income taxes
5,961,000,000 JPY
3,498,000,000 JPY
Gross profit
Extraordinary income
Gain on sale of non-current assets
4,000,000 JPY
0 JPY
Gain on sale of investment securities
45,000,000 JPY
JPY
Extraordinary losses
Loss on sale of investment securities
1,000,000 JPY
JPY
Income taxes
1,583,000,000 JPY
1,015,000,000 JPY
Profit (loss)
4,377,000,000 JPY
2,483,000,000 JPY
Profit (loss) attributable to owners of parent
4,377,000,000 JPY
2,483,000,000 JPY
Profit attributable to
Other comprehensive income
Valuation difference on available-for-sale securities
347,000,000 JPY
-889,000,000 JPY
Foreign currency translation adjustment
303,000,000 JPY
111,000,000 JPY
Share of other comprehensive income of entities accounted for using equity method
-3,000,000 JPY
24,000,000 JPY
Remeasurements of defined benefit plans, net of tax
274,000,000 JPY
240,000,000 JPY
Other comprehensive income
922,000,000 JPY
-512,000,000 JPY
Comprehensive income
5,300,000,000 JPY
1,971,000,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
5,300,000,000 JPY
1,971,000,000 JPY
Comprehensive income attributable to non-controlling interests
JPY
JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.